145 related articles for article (PubMed ID: 18691807)
1. Topical chemotherapy in human urothelial carcinoma explants: a novel translational tool for preclinical evaluation of experimental intravesical therapies.
Bolenz C; Ikinger EM; Ströbel P; Trojan L; Steidler A; Fernández MI; Honeck P; Gabriel U; Weiss C; Grobholz R; Alken P; Michel MS
Eur Urol; 2009 Sep; 56(3):504-11. PubMed ID: 18691807
[TBL] [Abstract][Full Text] [Related]
2. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
Xiao Z; Mak A; Koch K; Moore RB
BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
[TBL] [Abstract][Full Text] [Related]
3. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
[TBL] [Abstract][Full Text] [Related]
4. Complications of intravesical therapy for urothelial cancer of the bladder.
Koya MP; Simon MA; Soloway MS
J Urol; 2006 Jun; 175(6):2004-10. PubMed ID: 16697786
[TBL] [Abstract][Full Text] [Related]
5. Hydrostatic pressure enhances mitomycin C induced apoptosis in urothelial carcinoma cells.
Chen SK; Chung CA; Cheng YC; Huang CJ; Ruaan RC; Chen WY; Li C; Tsao CW; Hu WW; Chien CC
Urol Oncol; 2014 Jan; 32(1):26.e17-24. PubMed ID: 23403205
[TBL] [Abstract][Full Text] [Related]
6. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
7. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
[TBL] [Abstract][Full Text] [Related]
8. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
[TBL] [Abstract][Full Text] [Related]
9. Urothelial carcinoma with abundant myxoid stroma.
Tavora F; Epstein JI
Hum Pathol; 2009 Oct; 40(10):1391-8. PubMed ID: 19535127
[TBL] [Abstract][Full Text] [Related]
10. Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer.
Burks FN; Liu AB; Suh RS; Schuster TG; Bradford T; Moylan DA; Knapp PM; Murtagh DS; Dunn RL; Montie JE; Miller DC
J Urol; 2012 Dec; 188(6):2108-13. PubMed ID: 23083865
[TBL] [Abstract][Full Text] [Related]
11. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
Harris NM; Anderson WR; Lwaleed BA; Cooper AJ; Birch BR; Solomon LZ
Cancer; 2003 Jan; 97(1):71-8. PubMed ID: 12491507
[TBL] [Abstract][Full Text] [Related]
13. Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model.
Perabo FG; Demant AW; Wirger A; Schmidt DH; Sitia M; Wardelmann E; Müller SC; Kohn EC
Anticancer Res; 2005; 25(2A):725-9. PubMed ID: 15868902
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
15. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.
Hendricksen K; Moonen PM; van der Heijden AG; Molkenboer-Kuenen J; Hulsbergen-van de Kaa CA; Witjes JA
Clin Cancer Res; 2006 Apr; 12(8):2597-601. PubMed ID: 16638871
[TBL] [Abstract][Full Text] [Related]
16. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
17. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
[TBL] [Abstract][Full Text] [Related]
18. Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
Oosterlinck W
Nat Clin Pract Urol; 2006 Nov; 3(11):582-3. PubMed ID: 17088923
[No Abstract] [Full Text] [Related]
19. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
[TBL] [Abstract][Full Text] [Related]
20. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
